| Bioactivity | AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances the efficacy of Gemcitabine and Cisplatin in bladder cancer[1]. |
| Target | IC50: 27 nM (AKR1C3) |
| CAS | 891075-67-5 |
| Formula | C17H14N2O3 |
| Molar Mass | 294.30 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Rin Himura, et al. Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer. Chem Biol Interact. 2024 Jan 25:388:110840. |
AKR1C3-IN-12
CAS: 891075-67-5 F: C17H14N2O3 W: 294.30
AKR1C3-IN-12 (compound 2j) is an aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 of 27 nM. AKR1C3-IN-12 enhances
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.